Venture Capital

A new study shows the professional services market is slowing, but elite firms are widening the gap with a bold playbook of high investment and AI mastery.

A new partnership seeks to harness fault-tolerant quantum computers, promising to solve aerospace's most complex fluid dynamics problems.

Vericel posts strong 2025 results driven by its MACI cartilage therapy. The biotech leader is now investing in a new facility and a clinical trial for ankle repair.

With a former mayor and Airbnb policy chief now in its C-suite, EverDriven signals a push to rewrite the rules for getting vulnerable students to school.

A new partnership embeds Nasdaq's institutional data into Juniper Square's AI CRM, promising to end manual work for investor relations teams.

RAAPID’s award-winning Neuro-Symbolic AI brings transparency to risk adjustment, promising audit-ready accuracy and major ROI for value-based care.

With a fresh $130M and a key acquisition, Deepgram is building the infrastructure for a future where voice AI is as seamless as human conversation.

MedTech firm Lifeward is acquiring Oramed's oral insulin tech, despite a past trial failure, in a high-stakes deal that could redefine both companies.

A new fellowship in Newfoundland and Labrador aims to solve critical gaps in anesthesiology, boosting the region's health innovation ecosystem.

New data reveals couples are ditching performative trends for authentic celebrations, prioritizing personal stories, immersive experiences, and real-time content.

The high-power laser maker exceeded its Q4 guidance, driven by booming demand in aerospace and defense. Here's what it means for its 2026 outlook.

After a breakthrough CES demo, BookAI is raising capital to scale its platform that turns static books into interactive assets, breaking language barriers.

As Lithuania's grid operator faces a new era of digital demands and renewable integration, a former telecom CTO is set to take the lead in a major strategic shift.

A new US-French partnership brings fermentation-derived algal oils to Europe, promising superior performance and a traceable alternative to plant oils.

With a new lineup including a $699 model, ZWHAND's debut at CES 2026 could accelerate the mass adoption of dexterous robots in every field.

As Disc Medicine nears a potential drug launch, its new HR chief hire reveals a critical strategy for navigating biotech's intense talent wars.

Sonos adds leaders from Meta, e.l.f. Beauty, and Pandora to its board, signaling a strategic push into AI, platform growth, and financial discipline.

The biotech firm faces a delisting threat after its equity turned negative. Can recent funding save its Nasdaq spot and its ambitious drug pipeline?

The AI health-tech leader achieved profitability and massive growth in 2025, expanding its reach to nearly 2,000 hospitals and doubling its life sciences arm.

The investment firm celebrated a strong 2025 with shareholder payouts, fueled by profitable exits and a new major investment in AI infrastructure firm TensorWave.